Risk management and minimisation activities can include post-authorisation safety studies (PASS), review of the effectiveness of risk minimisation measures, monitoring pharmacovigilance risk assessment committee (PRAC) recommendations for signals and addressing PRAC safety related queries.
A risk management system is a set of pharmacovigilance activities and interventions designed to identify, characterise, prevent or minimise risks relating to medicinal products, including the assessment of the effectiveness of those interventions (EMEA/CHMP/96268/2005)